Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
Elizabeth E. Tolley(Family Health International 360), Raphael J. Landovitz(APLA Health), David M. Margolis(University of North Carolina at Chapel Hill), Marc Siegel(George Washington University), Sue Li(Fred Hutch Cancer Center), Andrea Jennings(Family Health International 360), Beatriz Grinsztejn(University of Maryland, Baltimore), Marybeth McCauley(Family Health International 360), Bertha Maseko, Ravindre Panchia(Chris Hani Baragwanath Hospital), Albert Liu(San Francisco Department of Public Health), Sahar Z. Zangeneh(Fred Hutch Cancer Center), Alex R. Rinehart, Joe Eron(University of North Carolina at Chapel Hill), Hilton Humphries(Centre for the AIDS Programme of Research in South Africa), Gordon Chau(Fred Hutch Cancer Center), Leslie Cottle(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 92
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
The Challenge of Finding a Cure for HIV Infection
|Science|2009|850
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|847